➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Moodys
McKesson
Baxter
Merck

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Empagliflozin; Linagliptin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01422876 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed Eli Lilly and Company Phase 3 2011-08-01 This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
NCT01422876 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed Boehringer Ingelheim Phase 3 2011-08-01 This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
NCT01734785 Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2013-01-01 This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin; Linagliptin; Metformin Hydrochloride

Condition Name

Condition Name for Empagliflozin; Linagliptin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 4
Healthy 3
Prediabetic State 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Empagliflozin; Linagliptin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 7
Diabetes Mellitus 7
Prediabetic State 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Empagliflozin; Linagliptin; Metformin Hydrochloride

Trials by Country

Trials by Country for Empagliflozin; Linagliptin; Metformin Hydrochloride
Location Trials
United States 67
Canada 12
Australia 9
Germany 6
Russian Federation 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Empagliflozin; Linagliptin; Metformin Hydrochloride
Location Trials
Georgia 4
Texas 4
Florida 4
North Carolina 3
Michigan 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Empagliflozin; Linagliptin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin; Linagliptin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Empagliflozin; Linagliptin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Empagliflozin; Linagliptin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Empagliflozin; Linagliptin; Metformin Hydrochloride
Sponsor Trials
Boehringer Ingelheim 7
Eli Lilly and Company 6
Institut für Pharmakologie und Präventive Medizin 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Empagliflozin; Linagliptin; Metformin Hydrochloride
Sponsor Trials
Industry 14
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.